Loading...
Market
Story
Organon to Acquire Dermavant and VTAMA Cream in $175 Million APA Deal
Sep 18, 2024, 11:35 AM
Organon has announced its acquisition of Dermavant, including its innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. The deal includes an upfront payment of $175 million, with additional payments up to $1.2 billion based on sales milestones. An additional $75 million is contingent on VTAMA's approval in AtD. This acquisition, structured as an APA, highlights Organon's commitment to expanding its dermatology portfolio.
View original story
Similar markets
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%